IBUPROXAM

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H19NO2
Molecular Weight	221.2955
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)CC1=CC=C(C=C1)C(C)C(=O)NO

InChI

InChIKey=BYPIURIATSUHDW-UHFFFAOYSA-N

InChI=1S/C13H19NO2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(15)14-16/h4-7,9-10,16H,8H2,1-3H3,(H,14,15)

HIDE SMILES / InChI

Molecular Formula	C13H19NO2
Molecular Weight	221.2955
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7193032 | https://www.ncbi.nlm.nih.gov/pubmed/15000431 | https://www.ncbi.nlm.nih.gov/pubmed/577862 | http://adisinsight.springer.com/drugs/800007978

Ibuproxam is a prodrug which metabolizes into ibuprofen and is therefore indicated for the treatment of pain and inflammation. Administration of oral ibuproxam resulted in a significantly higher plasma concentration than administration of an equal dose of ibuprofen after 45 minutes. Despite showing some promise as a NSAID ibuproxam does not appear to have been approved or marketed.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cyclooxygenase 89 Target ID: CHEMBL2095157 Sources: http://adisinsight.springer.com/drugs/800007978 \| http://pubs.acs.org/doi/abs/10.1021/jm00170a004	Inhibitor 8504		10000.0 nM [IC50]
Arachidonate 5-lipoxygenase 52 Target ID: P12527 Gene ID: 25290.0 Gene Symbol: Alox5 Target Organism: Rattus norvegicus (Rat) Sources: http://pubs.acs.org/doi/abs/10.1021/jm00165a017 \| https://www.ncbi.nlm.nih.gov/pubmed/2308149 \| https://www.ncbi.nlm.nih.gov/pubmed/3669019	Inhibitor 8504		5700.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain due to inflammation. 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/577862 https://www.ncbi.nlm.nih.gov/pubmed/577863	Primary		Phase I 438	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Antioxidant activity of NSAID hydroxamic acids.	2009-06	19564147
Characterization of ibuproxam binary and ternary dispersions with hydrophilic carriers.	2004-01	15000431
Thin layer chromatographic resolution of some 2-arylpropionic acid enantiomers using L-(-)-serine, L-(-)-threonine and a mixture of L-(-)-serine and L-(-)-threonine-impregnated silica gel as stationary phases.	2003-07	12884398
Comparative study of ibuproxam complexation with amorphous beta-cyclodextrin derivatives in solution and in the solid state.	2002-09	12191690
Anti-inflammatory agents: determination of ibuproxam and its metabolite humans. Correlation between bioavailability, tolerance and chemico-physical characteristics.	1980	7193032

Patents

Sample Use Guides

In Vivo Use Guide

Ibuproxam was administered orally to healthy volunteers as a 400 mg film tablet.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:31:19 GMT 2025` Edited by `admin` on `Mon Mar 31 18:31:19 GMT 2025`
Record UNII	O3LD16O96Z
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IBUDROS

Preferred Name

English

IBUPROXAM

Official Name

English

IBUPROXAM [MART.]

Common Name

English

Ibuproxam [WHO-DD]

Common Name

English

ibuproxam [INN]

Common Name

English

NSC-305528

Code

English

IBUPROXAM [MI]

Common Name

English

P-ISOBUTYLHYDRATROPOHYDROXAMIC ACID

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C257